Catalyst Event
Novartis AG (NVS) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/20/2026, 12:00:00 AM
Announced agreement on 2026-03-20 to acquire Pikavation Therapeutics for $2 billion upfront to gain its lead breast cancer asset; high impact expected due to strategic expansion in oncology.
Korean Translation
2026-03-20에 유방암 치료제 자산 확보를 위해 피카베이션 테라퓨틱스를 20억 달러에 인수하는 계약을 발표함. 전략적 확대로 인한 높은 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.
4/28/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
4/28/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend with an ex-dividend date of April 15, 2026, is scheduled.
4/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, announced on March 11, 2026, with an ex-dividend date of March 27, 2026. This represented a 3.1% increase from the prior dividend.
3/27/2026, 12:00:00 AM